Abstract:Background: The optimal biomarkers for early diagnosis, treatment, and prognosis of tuberous sclerosis complex (TSC)-associated epilepsy are not yet clear. This study identifies the crucial genes involved in the pathophysiology of TSC-associated epilepsy via a bioinformatics analysis. These genes may serve as novel therapeutic targets. Methods: Gene chip data sets (GSE62019 and GSE16969) comprising the data of patients with TSC-associated epilepsy and healthy control participants were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) in the GEO database were identified using the GEO2R gene expression analysis tool. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, Gene Ontology function, and protein-protein interaction (PPI) network analyses were then conducted. The results were analyzed using R language, and are presented in volcano plots, Venn diagrams, heatmaps, and enrichment pathway bubble charts. A gene set enrichment analysis (GSEA), was conducted to examine the KEGG pathways and crucial genes linked to TSC-associated epilepsy. The potential genes were compared with the genes listed in the Online Mendelian Inheritance in Man (OMIM) database and analyzed against the literature to determine their clinical significance. Finally, the expression of the key genes in the TSC-associated epilepsy mice cerebral cortex was examined through immunohistochemical staining. Results: The intersection of the GSE62019 and GSE16969 data sets revealed 151 commonly upregulated DEGs. The KEGG enrichment analysis indicated that these DEGs affected the occurrence and development of TSC-associated epilepsy by modulating complement and coagulation cascades, glycosaminoglycans in cancer, and extracellular matrix-receptor interactions. Four high-scoring clusters emerged, and podoplanin (PDPN) was identified as a key gene through the construction of a PPI network of the common DEGs using the Cytoscape software. A GSEA of the DEGs revealed that the common DEG PDPN was enriched in both data sets in pathways related to platelet activation, aggregation, and the glycoprotein VI (GPVI)-mediated activation cascade. Immunohistochemical staining revealed a significant elevation in PDPN expression in the cerebral cortex of mice with TSC-associated epilepsy. Conversely, the control group mice did not display any significantly positive neurons. Conclusions: The discovery of these crucial genes and signaling pathways extends understanding of the molecular processes underlying the development of TSC-associated epilepsy. Additionally, our findings may provide a theoretical basis for research into targeted clinical treatments.

Identification of mRNA expression biomarkers associated with epilepsy and response to valproate with co-expression analysis

A Pilot Study on Identifying Gene Signatures As Markers for Predicting Patient Response to Antiseizure Medications

WGCNA Combined with GSVA to Explore Biomarkers of Refractory Neocortical Epilepsy

Identification of hub genes significantly linked to temporal lobe epilepsy and apoptosis via bioinformatics analysis

Analysis and Construction of a Molecular Diagnosis Model of Drug-Resistant Epilepsy Based on Bioinformatics

Identification of hub genes significantly linked to tuberous sclerosis related-epilepsy and lipid metabolism via bioinformatics analysis

Characterization of Immune-Related Genes and Immune Infiltration Features in Epilepsy by Multi-Transcriptome Data

Polymorphisms of ABAT, SCN2A and ALDH5A1 May Affect Valproic Acid Responses in the Treatment of Epilepsy in Chinese.

Bioinformatic Analysis Identifies Key Transcriptome Signatures in Temporal Lobe Epilepsy

Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy

Identifying Novel Drug Targets for Epilepsy Through a Brain Transcriptome-Wide Association Study and Protein-Wide Association Study with Chemical-Gene-Interaction Analysis.

Screening for biomarkers of tuberous sclerosis complex-associated epilepsy: a bioinformatics analysis

SCN1A and SCN2A Polymorphisms Are Associated with Response to Valproic Acid in Chinese Epilepsy Patients

Effects of SCN1A and SCN2A Polymorphisms on Responsiveness to Valproic Acid Monotherapy in Epileptic Children

Correlation of MCT1 and ABCC2 Gene Polymorphisms with Valproic Acid Resistance in Patients with Epilepsy on Valproic Acid Monotherapy

Characterization, using comparative proteomics, of differentially expressed proteins in the hippocampus of the mesial temporal lobe of epileptic rats following treatment with valproate

Associations Between Genetic Variation in One-Carbon Metabolism and Leukocyte DNA Methylation in Valproate-Treated Patients with Epilepsy.

Effect of SCN1A and SCN2A gene polymorphisms on the efficacy of valproic acid treatment in Chinese children with epilepsy

A microRNA signature for valproate-induced steatosis in human hepatocytes and its application to predict fatty liver in paediatric epileptic patients on valproate therapy

Comparative proteomic analysis of differentially expressed proteins in hippocampus of developmental rats with mesial temporal lobe epilepsy following treatment with valproate

Influence of transporter genetic polymorphisms on valproic acid blood concentration and clinical efficacy of epilepsy patients